CRISPR-enhanced assessment of variants of unknown significance nominates oncology therapeutic targets and drug repositioning opportunities
Aurora Savino, Athanasios Oikonomou, Francesca Perrone, Riccardo Roberto De Lucia, Letizia De Pietri, Yousra Belattar, Luke Brown, Miguel L. Grau, Katrina McCarten, Hanna Najgebauer, Umberto Perron, Luca Azzolin, Alexandra Livanova, Paolo Cremaschi, Núria López, , Francesco Iorio
CRISPR-VUS identifies rare variants linked to gene dependency in cancer cell lines, prioritizing potential drivers and therapeutic targets through functional validation.
bioRxiv · Sep 12, 2026 · PreprintBioinformatics